A quinazoline-carbazole skeleton derivative and its antidiabetic activity
By synthesizing quinazoline-carbazole skeleton derivatives to target DYRK1A and TXNIP, the problem of reduced β-cell proliferation was solved, achieving the protective effect on pancreatic β-cells and anti-diabetic effects.
Patent Information
- Application Number
- CN202410086385.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-22
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2044-01-22
AI Technical Summary
Existing technologies are unable to effectively target and regulate TXNIP and DYRK1A, leading to reduced β-cell proliferation and consequently the occurrence and development of diabetes.
By synthesizing quinazoline-carbazole skeleton derivatives and designing them as small molecule inhibitors targeting DYRK1A and TXNIP, a series of quinazoline-carbazole skeleton derivatives were synthesized using multi-target drug design and combinatorial chemistry methods to protect pancreatic β cells, enhance insulin secretion, and improve cellular redox status.
Quinazoline-carbazole skeleton derivatives can effectively protect pancreatic β cells, enhance their proliferative capacity, reduce the risk of diabetes, and have significant anti-diabetic activity.
Smart Images

Figure CN117924252B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a quinazoline-carbazole skeleton derivative, its preparation method, and its use in the preparation of drugs for treating diabetes. Background Technology
[0002] Diabetes mellitus (DM) is one of the most important non-communicable diseases threatening global human health. Preventing and controlling the occurrence and progression of diabetes is urgently needed.
[0003] Pancreatic β-cells have low levels of antioxidant enzymes and are highly susceptible to oxidative stress. Thioredoxin-interacting protein (TXNIP) plays a crucial role in maintaining cellular redox status. In animal models, TXNIP overexpression has been shown to induce pancreatic β-cell apoptosis, and TXNIP-deficient animals are protected from diet-induced insulin resistance and type 2 diabetes. Targeting TXNIP can not only improve insulin secretion and sensitivity in pancreatic β-cells but also reduce various complications caused by long-term diabetes. Therefore, regulating TXNIP levels could serve as a novel therapeutic strategy to reduce the incidence of diabetes and its complications.
[0004] In studies on β-cell activity, small molecule inhibitors of bispecific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) have attracted increasing attention. In organoid experiments using human pancreatic islets, Barzowska et al. demonstrated that DYRK1A inhibitors can effectively promote β-cell proliferation, enhance long-term insulin secretion, and balance glucagon levels. Multiple experimental data related to DYRK1A and pancreatic β-cell proliferation show that when DYRK1A is haploidly deficient, mice develop severe glucose intolerance and a reduced number of β-cells, ultimately leading to diabetes. Therefore, DYRK1A inhibitors, which enhance β-cell proliferation, are one of the effective targets for anti-diabetic therapy.
[0005] In summary, the inventors hope to develop a quinazoline-carbazole skeleton derivative targeting DYRK1A and TXNIP for the treatment of diabetes. Summary of the Invention
[0006] Based on the fact that TXNIP and DYRK1A are good dual targets for the treatment of diabetes, the inventors synthesized a series of quinazoline-carbazole skeleton derivatives through the design concepts of "multi-target" drug design and "combinatorial chemistry" and explored their effects on diabetes, and found that the quinazoline-carbazole skeleton derivatives have anti-diabetic activity.
[0007] The quinazoline-carbazole skeleton derivative of structural formula I or a pharmaceutically acceptable salt thereof:
[0008]
[0009] Where n is an integer from 0 to 6;
[0010] R1 is selected from hydrogen, hydroxyl, methoxy, trifluoromethyl, and halogen; R2 is selected from hydrogen, hydroxyl, methoxy, trifluoromethyl, and halogen; R3 is selected from hydrogen, hydroxyl, methoxy, trifluoromethyl, and halogen; R4 is selected from hydrogen, methoxy, and hydroxyl.
[0011] Preferably, n is an integer from 0 to 3; R1 is selected from hydrogen and bromine; R2 is selected from hydrogen and bromine; R3 is selected from hydrogen and hydroxyl; and R4 is selected from hydrogen.
[0012] More preferably, when n = 1, R1 is selected from bromine, R2 is selected from hydrogen, R3 is selected from hydrogen, and R4 is selected from hydrogen; when n = 2 or 3, R1 is selected from hydrogen, R2 is selected from hydrogen, R3 is selected from hydroxyl group, and R4 is selected from hydrogen.
[0013] Specifically, the quinazoline-carbazole skeleton derivative is selected from compounds with the following structures:
[0014]
[0015]
[0016] Another object of the present invention is to provide a method for preparing the quinazoline-carbazole skeleton derivative, the synthetic route of which is as follows:
[0017]
[0018] Wherein: n, R1, R2, R3, R4 are as described above.
[0019] include:
[0020] Step (1): Using DMF as the reaction solvent, 4-hydroxyquinazoline as the substrate, and potassium carbonate as the acid-binding agent, under alkaline conditions, 4-hydroxyquinazoline reacts with... The compound shown reacts at room temperature to produce intermediate A;
[0021] Step (2): Using DMF as the reaction solvent, potassium carbonate as the acid-binding agent, and KI as the catalyst, intermediate A and compound Z are heated and refluxed to generate the quinazoline-carbazole skeleton derivative shown in Formula I.
[0022] In step (1), 4-hydroxyquinazoline and The molar ratio is 1:2 to 1:3.
[0023] The molar ratio of 4-hydroxyquinazoline to potassium carbonate is 1:3 to 1:5.
[0024] After the reaction was completed, water was added to the reaction solution at a volume ratio of 1:10 between the reaction solvent and water, crystals precipitated, and the solution was filtered to obtain intermediate A.
[0025] In step (2), the molar ratio of intermediate A to compound Z is 1:1 to 1:1.2.
[0026] The molar ratio of intermediate A to potassium carbonate is 1:2.8 to 1:3.
[0027] The mass ratio of KI to intermediate A is 3:100 to 4:100.
[0028] After the reaction was completed, ethyl acetate and water were added to the reaction solution, and the mixture was extracted. The organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified by silica gel column chromatography using petroleum ether and acetone in a volume ratio of 5:1 to 7:1 V / V to obtain the quinazoline-carbazole skeleton derivative shown in Formula I.
[0029] The inventors conducted an in vitro study on the protective effects of the quinazoline-carbazole skeleton derivatives on mouse Min6 pancreatic β cells and found that all compounds could protect pancreatic β cells from palmitic acid-induced damage and had different degrees of protective effects on pancreatic β cells.
[0030] The present invention also provides the use of the quinazoline-carbazole skeleton derivatives thereof or pharmaceutically acceptable salts thereof in the preparation of medicaments for treating diabetes.
[0031] A pharmaceutical composition comprising a quinazoline-carbazole skeleton derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and pharmaceutically acceptable excipients to form a pharmaceutically acceptable formulation.
[0032] The beneficial effects of this invention are:
[0033] This invention synthesizes quinazoline-carbazole skeleton derivatives through a two-step reaction with mild reaction conditions, easy reproducibility, and high yield.
[0034] This invention is the first to discover the pancreatic β-cell protective activity of a quinazoline-carbazole skeleton derivative, which is an ideal chemical entity for protecting pancreatic β-cells and a potential new chemical entity for the treatment of diabetes. It is of great significance for the research and development of anti-diabetic drugs. Detailed Implementation
[0035] The technical solution of the present invention will be further described in detail with reference to specific embodiments, but the present invention is not limited to the following embodiments.
[0036] The synthetic route from compound HZ-1 to compound HZ-8 is as follows:
[0037]
[0038] Example 1
[0039] Preparation of compounds A1-A3
[0040] 4-(3-Chloropropoxy)quinazoline (Compound A1)
[0041]
[0042] 2.00 g (13.68 mmol) of 4-hydroxyquinazoline and 5.70 g (41.24 mmol) of K₂CO₃ were placed in a 100 mL round-bottom flask and dissolved in 10 mL of DMF. Then, 2.70 mL (27.37 mmol) of 1-bromo-3-chloropropane was added to the flask. The reaction was allowed to proceed at room temperature for 1 h, and TLC was used to monitor the reaction until complete. 100 mL of water was added to the reaction system, and a large amount of white crystals precipitated. The crystals were filtered under reduced pressure to give compound A1, white crystals, 2.39 g, yield 91.97%.
[0043] mp: 206~209℃; 1 H NMR (400MHz, CDCl3) δ: 8.33 (1H, dd, J = 8.0, 0.9Hz, H-8), 8.11
[0044] (1H,s,H-3),7.78(1H,dt,J=17.6,4.4Hz,H-2),7.65~7.72(1H,m,H-1),4.21(2H,t,J =6.7Hz,OCH2-),3.62(2H,t,J=6.0Hz,CH2Cl-),2.33~2.40(2H,m,2H,-CH2-); ESI-MS m / z:223.1[M+H] + .
[0045] 4-(4-Chlorobutoxy)quinazoline (compound A2)
[0046]
[0047] 2.00 g (13.68 mmol) of 4-hydroxyquinazoline and 5.70 g (41.24 mmol) of K₂CO₃ were added to a 100 mL round-bottom flask. 10 mL of DMF was added to dissolve the flask, and then 3.15 mL (27.37 mmol) of 1-bromo-4-chlorobutane was added dropwise. The reaction was allowed to proceed at room temperature for 1 h, and TLC was used to monitor the reaction until complete. 100 mL of water was added to the reaction mixture, and after standing, a large amount of white crystals precipitated. The crystals were filtered under reduced pressure to give compound A2, white crystals, 2.47 g, yield 93.90%.
[0048] mp: 214~219℃; 1 H NMR (400MHz, CDCl3) δ8.31 (1H, dd, J = 8.0, 1.0Hz, H-8),
[0049] 7.95~8.15(1H,m,H-3),7.67~7.79(1H,m,H-2),7.50~7.61(1H,m,H-6),7.49~7.52(1H,m,H-1),3.96~4. 07(2H,m,OCH2-),3.60~3.69(2H,m,CH2Cl),2.01~2.12(2H,m,-CH2-),1.85~1.92(2H,m,-CH2-); ESI-MS m / z:237.1[M+H] + .
[0050] 4-(5-Chloropentoxy)quinazoline (compound A3)
[0051]
[0052] 2.00 g (13.68 mmol) of 4-hydroxyquinazoline and 5.70 g (41.24 mmol) of K₂CO₃ were added to a 100 mL round-bottom flask, dissolved in 10 mL of DMF, and then 3.73 mL (27.36 mmol) of 1-bromo-5-chloropentane was added dropwise. The reaction was allowed to proceed at room temperature for 1 h, and TLC was used to monitor the reaction until it was complete. 100 mL of water was added to the reaction solution, and the mixture was allowed to stand. A large amount of white crystals precipitated. The crystals were filtered under reduced pressure to obtain 2.82 g of white crystals, with a yield of 94.05%.
[0053] mp 221~22℃; 1 H NMR (400MHz, CDCl3) δ: 8.31 (1H, dd, J = 8.0, 1.1Hz, H-8), 8.05 (1H,
[0054] d,J=5.9Hz,H-3),7.75~7.84(2H,m,H-2,H-6),7.52~7.61(1H,m,H-1),4.02(2H,t,J=7.4Hz,OCH2-),3.55 (2H,t,J=6.5Hz,CH2Cl),1.83(4H,dd,J=14.9,7.1Hz,-CH2-CH2-),1.56-1.64(2H,m,-CH2-CH2-); ESI-MS m / z:251.0[M+H] + .
[0055] Example 2
[0056] 2-Bromo-9-(3-(quinazolin-4-yloxy)propyl)-9H-carbazole (compound HZ-1)
[0057]
[0058] 100 mg (0.45 mmol) of compound A1 and 111 mg (0.50 mmol) of 2-bromocarbazole were dissolved in 5 mL of LMF. 186 mg (1.35 mmol) of K2CO3 and 3 mg of KI were added, and the mixture was heated under reflux at 120 °C for 8 h. The reaction was monitored by TLC until complete. 30 mL of ethyl acetate was added to the reaction mixture, and the mixture was extracted with water (30 mL × 3). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. Separation by silica gel column chromatography (petroleum ether:acetone = 5:1 V / V) yielded compound HZ-1, a white crystalline solid, 179.28 mg, in 92.2% yield.
[0059] mp: 117~119℃; 1 H NMR (400MHz, CDCl3) δ: 8.33 (1H, d, J = 7.8Hz, H-8), 8.15 (1H, s,
[0060] H-3),7.97~8.11(2H,m,Ph-H),7.96(2H,t,J=8.6Hz,H-2,H-6),7.79(1H,t,J=7.6Hz,Ph-H),7.61(1H,s,H-1),7.56(1H,s,Ph-H),7.51~7.59(1H, m,Ph-H),7.38(2H,dd,J=11.7,6.5Hz,Ph-H),4.46(2H,t,J=6.9Hz,CH2N-),3.95~4.13(2H,m,-CH2-),2.44(2H,dd,J=12.9,5.4Hz,-CH2-); ESI-MS m / z:244.0[M+H] + .
[0061] Example 3
[0062] 3-Bromo-9-(3-(quinazolin-4-yloxy)propyl)-9H-carbazole (compound HZ-2)
[0063]
[0064] 100 mg (0.45 mmol) of compound A1 and 111 mg (0.50 mmol) of 3-bromocarbazole were dissolved in 5 mL of DMF. 186 mg (1.35 mmol) of K2CO3 and 3 mg of KI were added, and the mixture was heated under reflux at 120 °C for 8 h. The reaction was monitored by TLC until complete. 30 mL of ethyl acetate was added to the reaction system, and the mixture was extracted with water (30 mL × 3). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. Separation by silica gel column chromatography (petroleum ether:acetone = 5:1 V / V) yielded compound HZ-2, a white crystalline solid, 185.56 mg, in 95.7% yield.
[0065] mp: 123~126℃; 1 H NMR (400MHz, CDCl3) δ: 8.31(1H,s,H-8),8.19(1H,s,Ph-H),8.06(1H,s,H-3),7.77(2H, d,J=8.5Hz,H-2,H-6),7.69(1H,d,J=7.7Hz,Ph-H),7.54(1H,s,Ph-H),7.52(1H,s,H-1), 7.46(1H,s,Ph-H),7.42(1H,s,Ph-H),7.39(1H,s,Ph-H),7.28(1H,s,Ph-H),4.44(2H,d d,J=8.6,5.1Hz,CH2N-),4.00~4.12(2H,m,CH2O-),2.40(2H,t,J=5.7Hz,-CH2-); ESI-MS m / z:432.0[M+H] + .
[0066] Example 4
[0067] 9-(3-(quinazolin-4-yloxy)propyl)-9H-carbazole-4-ol (compound HZ-3)
[0068]
[0069] 100 mg (0.45 mmol) of compound A1 and 82 mg (0.45 mmol) of 4-hydroxycarbazole were dissolved in 5 mL of DMF. 186 mg (1.35 mmol) of K2CO3 and 3 mg of KI were added, and the mixture was heated under reflux at 120 °C for 8 h. The reaction was monitored by TLC until complete. 30 mL of ethyl acetate was added to the reaction system, and the mixture was extracted with water (30 mL × 3). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. Separation by silica gel column chromatography (petroleum ether:acetone = 6:1 V / V) yielded compound HZ-3, a yellow solid, 148.19 mg, in 89.3% yield.
[0070] mp: 145~149℃; 1 H NMR (400MHz, CDCl3) δ: 8.47 (1H, d, J = 9.3Hz, OH-), 8.30 (1H,
[0071] d,J=7.8Hz,H-8),8.07(1H,s,Ph-H),8.04(1H,s,H-3),7.75(2H,m,H-2,H-6 ),7.67(1H,d,J=7.8Hz,Ph-H),7.54(1H,s,H-1),7.52(1H,d,J=7.9Hz,Ph-H ),7.40~7.54(2H,m,Ph-H),7.08(1H,d,J=8.1Hz,Ph-H),6.64(1H,d,J=8.0H z,Ph-H),4.42(2H,s,CH2N-),4.30(2H,s,CH2O-),2.53(2H,s-CH2-); ESI-MS m / z:370.1[M+H] + .
[0072] Example 5
[0073] 2-Bromo-9-(4-(quinazolin-4-yloxy)butyl)-9H-carbazole (compound HZ-4)
[0074]
[0075] Compound A2 (100 mg, 0.42 mmol) and 2-bromocarbazole (94 mg, 0.42 mmol) were dissolved in 5 mL of DMF. 175 mg (1.26 mmol) of K2CO3 and 3 mg of KI were added, and the mixture was heated under reflux at 120 °C for 8 h. The reaction was monitored by TLC until complete. 30 mL of ethyl acetate was added to the reaction mixture, and the mixture was extracted with water (30 mL × 3). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. Separation by silica gel column chromatography (petroleum ether:acetone = 5:1 V / V) yielded compound HZ-4, a white crystalline solid, 168.19 mg, in 94.5% yield.
[0076] mp: 152~157℃. 1 H NMR (400MHz, CDCl3) δ: 8.33 (1H, d, J = 7.6Hz, H-8), 8.13 (1H,
[0077] s,H-3),8.04~8.15(2H,m,Ph-H),7.92(2H,dd,J=8.2,4.7Hz,H-2,H-6),7.69(1H,d,J=8.1Hz,Ph-H),7.57(1H,s,H- 1),7.55(1H,s,Ph-H),7.52(1H,d,J=7.7Hz,Ph-H),7.33~7.41(2H,m,Ph-H),4.33(2H,t,J=6.7Hz,CH2N-),3.95(2H t,J=7.0Hz,CH2O-),1.95(2H,dd,J=15.0,6.8Hz,-CH2-CH2N-),1.86(2H,dd,J=9.2,5.9Hz,CH2-CH2O-); ESI-MS m / z:446.0[M+H] + .
[0078] Example 6
[0079] 9-(4-(quinazolin-4-yloxy)butyl)-9H-carbazole-4-ol (compound HZ-5)
[0080]
[0081] 100 mg (0.42 mmol) of compound A2 and 77 mg (0.42 mmol) of 4-hydroxycarbazole were dissolved in 5 mL of DMF. 175 mg (1.26 mmol) of K2CO3 and 3 mg of KI were added, and the mixture was heated under reflux at 120 °C for 8 h. The reaction was monitored by TLC until complete. 30 mL of ethyl acetate was added to the reaction system, and the mixture was extracted with water (30 mL × 3). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. Separation by silica gel column chromatography (petroleum ether:acetone = 6:1 V / V) yielded compound HZ-5, a pale yellow solid, 152.60 mg, with a yield of 94.2%.
[0082] mp: 118~122℃. 1 H NMR (400MHz, CDCl3) δ: 8.35 (1H, t, J = 7.0 Hz, -OH), 8.29 (1H, t,
[0083] J=15.9Hz,H-8),8.09(1H,s,Ph-H),8.05(1H,d,J=29.1Hz,H-3),7.83~7.92(2H,m, H-2,H-6),7.60~7.72(1H,m,Ph-H),7.54(1H,t,J=5.7Hz,H-1),7.42~7.50(1H,m,P h-H),7.33~7.39(3H,m,Ph-H),7.25(1H,d,J=7.8Hz,Ph-H),4.25(d,J=45.6Hz,2H) ,4.14(2H,d,J=4.7Hz,2H),2.17(2H,d,J=4.5Hz,CH2-),1.63(s,2H,CH2-); ESI-MS m / z:384.1[M+H] + .
[0084] Example 7
[0085] 2-Bromo-9-(5-(quinazolin-4-yloxy)pentyl)-9H-carbazole (compound HZ-6)
[0086]
[0087] 100 mg (0.40 mmol) of compound A3 and 89 mg (0.40 mmol) of 2-bromocarbazole were dissolved in 5 mL of DMF. 165 mg (1.19 mmol) of K2CO3 and 3 mg of KI were added, and the mixture was heated under reflux at 120 °C for 8 h. The reaction was monitored by TLC until complete. 30 mL of ethyl acetate was added to the reaction mixture, and the mixture was extracted with water (30 mL × 3). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. Separation by silica gel column chromatography (petroleum ether:acetone = 6:1 V / V) yielded compound HZ-6, a white crystalline solid, 162.14 mg, in a yield of 93.10%.
[0088] mp: 152~157℃; 1 H NMR (400MHz, CDCl3) δ: 8.33 (1H, s, H-8), 8.06 (1H, d, J = 5.8Hz,
[0089] H-3),7.94(1H,s,Ph-H),7.76~7.80(2H,m,Ph-H),7.56(2H,t,J=14.3Hz,H-2,H -6),7.47(1H,d,J=13.5Hz,H-1),7.41(1H,d,J=6.2Hz,Ph-H),7.34(1H,s,Ph-H) ,7.27(2H,d,J=14.4Hz,Ph-H),4.18(2H,m,CH2N-),3.78(2H,dd,J=17.7,7.3Hz ,CH2O-),2.00~2.31(4H,m,-CH2),1.50(2H,dd,J=34.2,26.6Hz,-CH2-); ESI-MS m / z: 460.0 [M+H] + .
[0090] Example 8
[0091] 9-4-(quinazolin-4-yloxy)butyl)-9H-carbazole (compound HZ-7)
[0092]
[0093] 100 mg (0.42 mmol) of compound A2 and 70 mg (0.42 mmol) of carbazole were dissolved in 5 mL of DMF. 175 mg (1.26 mmol) of K2CO3 and 3 mg of KI were added, and the mixture was heated under reflux at 120 °C for 8 h. The reaction was monitored by TLC until complete. 30 mL of ethyl acetate was added to the reaction system, and the mixture was extracted with water (30 mL × 3). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. Separation by silica gel column chromatography (petroleum ether:acetone = 7:1 V / V) yielded compound HZ-7, a yellow crystal, 147.91 mg, in a yield of 95.43%.
[0094] mp: 126~130℃; 1H NMR (400MHz, CDCl3) δ: 8.34~8.28(1H,m,H-8),8.17(1H,s,Ph-H),8.11(1H,s,Ph-H),8.03(1H,d,J= 6.1Hz,H-3),7.75(2H,dd,J=14.3,6.3Hz,H-2,H-6),7.71~7.64(1H,m,Ph-H),7.60(1H,d,J=5.8Hz,P h-H),7.55(1H,d,J=6.3Hz,H-1),7.52(1H,s,Ph-H),7.47(1H,s,Ph-H),7.21(2H,s,Ph-H),4.90(2H, d,J=13.7Hz,CH2N-),3.96(2H,d,J=13.6Hz,CH2O-),1.98(2H,s,-CH2-),1.85(2H,s,-CH2-); ESI-MS m / z:345.1[M+H] + .
[0095] Example 9
[0096] 9-(5-(quinazolin-4-epoxy)pentyl)-9H carbazole (compound HZ-8)
[0097]
[0098] 100 mg (0.40 mmol) of compound A3 and 67 mg (0.40 mmol) of carbazole were dissolved in 5 mL of DMF. 165 mg (1.19 mmol) of K2CO3 catalyst and 3 mg of KI were added, and the mixture was heated under reflux at 120 °C for 8 h. The reaction was monitored by TLC until complete. 30 mL of ethyl acetate was added to the reaction mixture, and the mixture was extracted with water (30 mL × 3). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. Separation by silica gel column chromatography (petroleum ether:acetone = 7:1 V / V) yielded compound HZ-8, a white crystalline solid, 142.64 mg, in a yield of 93.82%.
[0099] mp: 132~136℃; 1 H NMR (400MHz, CDCl3) δ: 8.43 (1H, s, H-8), 8.16 (1H, d, J = 5.8Hz,
[0100] H-3),7.84(1H,s,Ph-H),7.66~7.74(2H,m,Ph-H),7.54~7.61(2H,t,J=14.3Hz,H-2,H-6),7.43(1H,d,J=13.5Hz,pH -H),4.81(2H,d,J=33.7Hz,CH2N-),3.91(2H,d,J=68.6Hz,CH2O-),2.00(2H,s,-CH2-),1.95(2H,s,-CH2-); ESI-MS m / z:367.1[M+H] + .
[0101]
[0102] Table 1. Quinazoline-carbazole skeleton derivatives of the present invention
[0103]
[0104] Example 10
[0105] Protective effect of quinazoline-carbazole skeleton derivatives on palmitic acid-stimulated pancreatic β cells
[0106] (1) Experimental Principle
[0107] Insulin secreted by pancreatic islet cells can lower blood sugar. Therefore, hypoglycemic drugs have a protective effect on pancreatic islet cells. Palmitic acid-induced apoptosis of pancreatic β-cells is a commonly used in vitro model of diabetic injury. By comparing the cell viability of the compound and the palmitic acid injury model, we can determine whether the compound has a protective effect on pancreatic β-cells.
[0108] (2) Cell culture and passage
[0109] Cells were cultured at 37°C in an incubator containing 5% CO2. Cell passage was performed when cell confluence reached 80%. Complete culture medium was aspirated, and the cells were washed twice with PBS buffer. 1 mL of 0.25% EDTA trypsin was added, and the cells were digested for 1.5 min. Complete culture medium (DMEM + 1% triple antibody + 10% fetal bovine serum) was then added, and the cells were resuspended by pipetting. The cells were centrifuged at 1000 rpm for 5 min, the supernatant was discarded, and the cell pellet was resuspended in fresh culture medium and evenly spread into T25 culture flasks. The flasks were then placed in a cell culture incubator for further culture.
[0110] (3) Solution preparation
[0111] 10% Bovine Serum Albumin (BSA): Accurately weigh 1.0 g of BSA powder, dissolve it thoroughly in PBS buffer and bring the volume to 10 mL, filter to sterilize, dispense into containers, and store at -20°C for later use.
[0112] Preparation of palmitic acid (PA) working solution: Accurately weigh 30.77 mg PA powder, add 1 mL of anhydrous ethanol and dissolve by sonication or by heating in a 60°C water bath. Then add 3 mL of 50 nmol / L NaOH solution to prepare a 30 mmol / L working solution. Filter for sterilization and prepare immediately before use. Before use, dilute with DMEM medium containing 0.55% fatty acid-free BSA at a ratio of 1:100.
[0113] Preparation of compound solutions: Accurately weigh the compounds separately, add dimethyl sulfoxide to dissolve the compounds to prepare a 100 mmol / L storage solution, then dilute with PBS buffer to prepare a 1 mmol / L working solution, store at -20℃ for later use; before use, dilute the working solution with BSA-free DMEM medium to prepare a 10 μmol / L test solution.
[0114] (4) Determine the protective effect of the drug on pancreatic islet cells under palmitic acid stimulation.
[0115] When the confluence of Min6 cells reached 80%, the cells were evenly seeded into 96-well culture plates and cultured overnight at 37°C in a 5% CO2 incubator. A PA treatment group was set up, in which a cell damage model was constructed using 0.3 mmol / L PA; the test solution containing the compound was added to a final concentration of 10 μmol / L and incubated for another 24 h. Cell viability was then measured using the CCK8 reagent.
[0116] (5) Experimental Results
[0117] Table 2. Protective activity of the compounds against PA-stimulated Min6 cells at 10 μmol / L
[0118]
[0119] As shown in Table 2, all compounds exhibited varying degrees of protection against pancreatic β-cells, with cell viability exceeding 60%, which was higher than that of the PA-stimulated cell injury model (cell viability of 40.1%). Among them, compounds HZ-5 and HZ-6 showed protective effects exceeding 80%, with cell viability of 88.4% and 82.3%, respectively.
[0120] In general, the quinazoline-carbazole skeleton derivatives of this invention all exhibit varying degrees of pancreatic islet cell protection, representing a novel chemical entity for antidiabetic purposes.
Claims
1. A quinazoline-carbazole skeleton derivative with the structure shown in Formula I, or a pharmaceutically acceptable salt thereof: in: n = 0 to 6; R1 is hydrogen, hydroxyl, methoxy, trifluoromethyl, or halogen; R2 is hydrogen, hydroxyl, methoxy, trifluoromethyl, or halogen; R3 is hydrogen, hydroxyl, methoxy, trifluoromethyl, or halogen; R4 is hydrogen, methoxy, hydroxyl, or trifluoromethyl.
2. The quinazoline-carbazole skeleton derivative according to claim 1, characterized in that: n = an integer from 0 to 3; R1 is selected from hydrogen and bromine; R2 is selected from hydrogen and bromine; R3 is selected from hydrogen and hydroxyl; R4 is selected from hydrogen.
3. Quinazoline-carbazole skeleton derivatives with structures as shown in Formula I, or pharmaceutically acceptable salts thereof: in: For n=1, R1 is selected from bromine, R2 is selected from hydrogen, R3 is selected from hydrogen, and R4 is selected from hydrogen; for n=2 or 3, R1 is selected from hydrogen, R2 is selected from hydrogen, R3 is selected from hydroxyl group, and R4 is selected from hydrogen.
4. A quinazoline-carbazole skeleton derivative or a pharmaceutically acceptable salt thereof, characterized in that: The quinazoline-carbazole skeleton derivatives are selected from the following compounds:
5. A method for preparing the quinazoline-carbazole skeleton derivative according to claim 1, characterized in that: The synthesis route is as follows: Wherein: n, R1, R2, R3, and R4 are as described in claim 1.
6. The method for preparing the quinazoline-carbazole skeleton derivative according to claim 5, characterized in that: include: Step (1): Using DMF as the reaction solvent, 4-hydroxyquinazoline as the substrate, and potassium carbonate as the acid-binding agent, under alkaline conditions, 4-hydroxyquinazoline reacts with... The compound shown reacts at room temperature to produce intermediate A; Step (2): Using DMF as the reaction solvent, potassium carbonate as the acid-binding agent, and KI as the catalyst, intermediate A and compound Z are heated and refluxed to generate the quinazoline-carbazole skeleton derivative shown in Formula I.
7. The method for preparing the quinazoline-carbazole skeleton derivative according to claim 6, characterized in that: In step (1), 4-hydroxyquinazoline and The molar ratio of 1:2 to 1:3; the molar ratio of 4-hydroxyquinazoline to potassium carbonate is 1:3 to 1:
5.
8. The method for preparing the quinazoline-carbazole skeleton derivative according to claim 6, characterized in that: In step (2), the molar ratio of intermediate A to compound Z is 1:1 to 1:1.2; the molar ratio of intermediate A to potassium carbonate is 1:2.8 to 1:
3. The mass ratio of KI to intermediate A is 3:100 to 4:
100.
9. Use of the quinazoline-carbazole skeleton derivative of any one of claims 1-4 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating diabetes.
10. A pharmaceutical composition, characterized in that: The pharmaceutical composition is formulated into a pharmaceutically acceptable formulation using the quinazoline-carbazole skeleton derivative or a pharmaceutically acceptable salt thereof as the active ingredient and pharmaceutically acceptable excipients as described in any one of claims 1-4.
Citation Information
Patent Citations
Series of quinazoline sugar derivatives used as protein tyrosine kinase inhibitor, preparation method and application thereof
CN101857618A
Preparation method of dapoxetine hydrochloride impurities
CN107935866A
